Aperio unveils new digital IHC system

Aperio Technologies has launched an FDA cleared digital immunohistochemistry (IHC) system that allows pathologists to run quantitative IHC image analysis while reading slides on a computer monitor.

The Vista, Calif.-based company said that the digital IHC system includes FDA-cleared algorithms for HER2, ER and PR stained breast specimens for diagnosing digital slides for clinical use in pathology. Also, the system comes with a suite of image analysis algorithms that can be tuned for different tissue types (e.g. breast, colon, prostate), stains (e.g. HER2, ER, PR, Ki-67, P53, EGFR), reagents (e.g. Dako, Ventana) or to correlate algorithm results with other test methods (e.g. FISH, CISH).

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.